Esreboxetine  (Synonyms: (S,S)-(+)-Reboxetine)

Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain^[1].

313.39

C₁₉H₂₃NO₃

98819-76-2

CCOC(C=CC=C1)=C1O[C@H]([C@]2([H])CNCCO2)C3=CC=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Erik H. F. Wong, Saeeduddin Ahmed, et al. Highly selective norepinephrine reuptake inhibitors and methods of using the same. WO2001001973A2

  [2]. Fleishaker JC, Mucci M, Pellizzoni C, Poggesi I. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos. 1999 Jan;20(1):53-7.

  [3]. Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther. 1999 Oct;66(4):374-9.  [Content Brief]